mafosfamide has been researched along with Melanoma in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gambacorti-Passerini, C; Parmiani, G; Rivoltini, L; Supino, R | 1 |
Myers, DE; Vallera, DA | 1 |
Erba, E; Fossati, G; Gambacorti-Passerini, C; Parmiani, G; Radrizzani, M | 1 |
Hoon, DB; Jung, T; McBride, WH; Morton, DL; Naungayan, J; Nizze, A | 1 |
1 review(s) available for mafosfamide and Melanoma
Article | Year |
---|---|
Immunotoxins containing ricin.
Topics: Ammonium Chloride; Antibodies, Monoclonal; Cross-Linking Reagents; Cyclophosphamide; Drug Evaluation; Drug Synergism; Galactose; Humans; Immunotoxins; Leukemia; Melanoma; Neoplasms; Receptors, Mitogen; Ricin; Yttrium | 1988 |
3 other study(ies) available for mafosfamide and Melanoma
Article | Year |
---|---|
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line; Cisplatin; Cyclophosphamide; Cytotoxicity, Immunologic; Doxorubicin; Drug Resistance; Humans; Killer Cells, Natural; Lymphocyte Activation; Lymphokines; Melanoma; Tumor Cells, Cultured | 1989 |
Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide.
Topics: Carcinoma, Small Cell; Cell Line; Clone Cells; Cyclophosphamide; Flow Cytometry; Fluorometry; Humans; Immunotherapy; In Vitro Techniques; Interleukin-2; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Melanoma | 1987 |
Cyclophosphamide-induced alterations in human monocyte functions.
Topics: Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Humans; Immunity, Cellular; Interleukin-1; Leukocytes, Mononuclear; Melanoma; Tumor Necrosis Factor-alpha; Vaccination | 1987 |